Home/Investors/EcoR1 Capital

EcoR1 Capital

Biotech Investor · 7 portfolio companies

Portfolio

7

Combined Value

$11.3B

Focus Areas

16

Top Stage

Phase 3

Investment Focus

Neuromuscular Cardiometabolic Disorders Immuno-Oncology Fibrotic Diseases Hematology Cardiometabolic Oncology Fibrosis Respiratory Metabolic Genetics & Genomics Neuroscience Rare Disease Respiratory Diseases Genetic Disorders

Portfolio Companies

Company	Stage	Valuation	Focus
Scholar Rock Holding	Phase 3	$5.7B	Neuromuscular, Cardiometabolic Disorders
Scholar Rock	Phase 3	$5.6B	Neuromuscular, Cardiometabolic
ReCode Therapeutics	phase-1	—	Respiratory, Metabolic
Accent Therapeutics	preclinical	—	Oncology
Atalanta Therapeutics	preclinical	—	Neuroscience, Rare Disease
Ethris	Pre-clinical	—	Respiratory Diseases, Genetic Disorders
Scorpion Therapeutics	phase-1	—	Oncology

Frequent Co-Investors

Atlas Venture3 shared ARCH Venture Partners2 shared Polaris Partners2 shared Timothy Springer2 shared OrbiMed1 shared The Column Group1 shared Boxer Capital1 shared Bristol Myers Squibb1 shared